MAIA Biotechnology Files 8-K
Ticker: MAIA · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Mar 8, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, exhibits
TL;DR
MAIA Bio files 8-K, mostly financial docs. No major news yet.
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on March 8, 2024, reporting an event on March 6, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates MAIA Biotechnology, Inc. is providing updated financial information or exhibits to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate significant operational or financial changes.
Key Numbers
- 001-41455 — SEC File Number (Identifies the company's filing with the SEC)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- March 6, 2024 (date) — Earliest event date
- March 8, 2024 (date) — Filing date
- 001-41455 (company) — SEC File Number
- 444 West Lake Street, Suite 1700 Chicago, IL 60606 (company) — Principal executive offices address
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided text states the filing includes 'Financial Statements and Exhibits' but does not list the specific documents.
What is the nature of the 'Other Events' reported on March 6, 2024?
The filing indicates 'Other Events' were reported, but the specific details of these events are not elaborated in the provided excerpt.
What is MAIA Biotechnology, Inc.'s primary business sector?
MAIA Biotechnology, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are MAIA Biotechnology, Inc.'s principal executive offices located?
The principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2024-03-08 16:15:28
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 21KB
- ex99-2.htm (EX-99.2) — 24KB
- ex99-3.htm (EX-99.3) — 15KB
- 0001493152-24-009400.txt ( ) — 290KB
- maia-20240306.xsd (EX-101.SCH) — 3KB
- maia-20240306_lab.xml (EX-101.LAB) — 33KB
- maia-20240306_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 6, 2024 99.2 Press Release dated March 6, 2024 99.3 Press Release dated March 7, 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 8, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3